The most recent paused research includes Mersana Therapeutics’ phase 3 UP-NEXT and phase 1 UPGRADE-A trials, which are testing UpRi in platinum-sensitive ovarian cancer. Current study participants are allowed to continue the treatment, but the FDA paused further enrollment.
The partially blocked study follows reports of five fatal bleeding events happening among about 560 patients, Mersana said June 15. The day prior, 2seventy Bio paused a phase 3 trial for a leukemia drug candidate after the first patient to take the medication died.
All reported deaths are under investigation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.